TheraRadar
← Back
Data updated: Mar 29, 2026

SOBI

OncologyImmunologyDermatology
Pharma

SOBI is a pharmaceutical company focused on Oncology, Immunology, Dermatology. Key products include VONJO.

2022
Since
1
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

VONJO
pacritinib citrate
ACVR1 1 indications · 2022

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

VONJO 2025-10-01
Labeling
VONJO 2025-08-22
Labeling
VONJO 2024-11-12
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 65%
0 drugs Phase 3: 1 Phase 1: 9
Immunology 15%
0 drugs Phase 1: 3
Dermatology 15%
0 drugs Phase 2: 1 Phase 1: 1
Metabolic 5%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Dermatology
Pfizer big-pharma
Oncology, Dermatology, Immunology
Merck big-pharma
Oncology, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Immunology